The aim of this article is to review rheumatological diseases that are associated with glucocorticoid-induced osteoporosis or fractures and to perform a critical analysis of the current guidelines and treatment regimens. The electronic database MEDLINE was searched using the date range of July 1986 to June 2009 and the following search terms: osteoporosis, bone mineral density, fractures, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, vasculitis, juvenile rheumatoid arthritis, juvenile idiopathic arthritis and juvenile dermatomyositis. Osteopenia and osteoporosis respectively account for 1.4 to 68.7% and 5.0 to 61.9% of adult rheumatological diseases. Among juvenile rheumatological disorders, the frequency of low bone mass ranges from 38.7 to 70%. In general, fracture rates vary from 0 to 25%. Although glucocorticoid-induced osteoporosis has a high rate of prevalence among rheumatic diseases, a relatively low number of patients on continuous glucocorticoid treatment receive adequate diagnostic evaluation or preventive therapy. This deficit in patient care may result from a lack of clear understanding of the attributed risks by the patients and physicians, the high complexity of the treatment guidelines and poor patient compliance.
Glucocorticoids (GC) are frequently used for the management of patients with rheumatological diseases. The use of GC, however, is associated with a variety of adverse effects,1 including the development of osteoporosis and fractures. In patients who have received GCs for longer than six months, the estimated glucocorticoid-induced osteoporosis (GIO) frequency is 50%.2 One-third to one-half of long-term GC users may develop fractures. Furthermore, the risk of fractures strongly correlates with the daily and cumulative dose of GC and does not seem to correlate with the specific underlying disease.3 The underlying diseases for which GCs are prescribed, however, usually carry a risk of osteoporosis. The objective of the present study was to review rheumatic diseases in which GIO fractures have been described and to perform a critical analysis of the diagnostic criteria of osteoporosis and low bone mass. In addition, the current guidelines and treatment barriers for the management of GIO will be discussed.
PathophysiologyThe pathogenesis of GIO is multifaceted. Glucocorticoids have indirect effects on osteoporosis by inhibiting calcium absorption from the gastrointestinal track and decreasing the renal tubular reabsorption of calcium and consequentely secondary hyperparathyroidism. Nevertheless, hyperparathyroidism does not play a central role in the pathogenesis of GIO, snce the most of patients using chronic GC present normal levels of serum parathromone. GCs reduce growth hormone (GH) secretion and may alter the GH/insulin-like growth factor (IGF)-I axis; however, the serum levels of IGF-I are normal during osteoporosis, suggesting that alterations in the GH/IGF-I axis play a minor role in this skeletal disease. A more important role may be played by skeletal IGF-I because GCs inhibit IGF-I transcription in osteoblasts. In addition, GCs inhibit the release of gonadotrophins and the resulting hypogonadism may contribute to skeletal disease.3
Glucocorticoids have direct effects on bone cells. Bone histomorphometric analyses of biopsies obtained from patients with GIO reveal decreased bone turnover with a disproportionate reduction in bone formation. GCs reduce the replication, differentiation and function of osteoblasts4 and increase the apoptosis rates of mature cells, thereby depleting the osteoblastic cell population and inhibiting the function of mature cells.3 Furthermore, in the presence of GCs, bone marrow stromal cells do not differentiate into osteoblasts; instead, these cells differentiate toward an adipocyte cell lineage. The underlying mechanism for this change in cell fate appears to be related to an induction of CCAAT enhancer binding proteins and possibly by inhibiting Wingless (Wnt)/β-catenin signaling.3 Moreover, GCs induce apoptosis in osteocytes and affect the functioning of these cells. GCs increase the expression of macrophage colony stimulating factor (M-CSF) and receptor activator of Nuclear fator kappa beta (NF-kB) ligand (RANK-L). In addition, GCs decrease the expression of osteoprotegerin in stromal and osteoblastic cells. Through these mechanisms, GCs can induce the formation of osteoclasts and favor bone resorption. GCs also reduce the rate of apoptosis among mature osteoclasts.3
GIO in Rheumatic DiseasesThe electronic database MEDLINE was searched using the date range of July 1986 to June 2009 and the following search terms: osteoporosis, bone mineral density, fractures, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, juvenile rheumatoid arthritis, juvenile idiopathic arthritis and juvenile dermatomyositis. A total of 17 studies were found regarding systemic lupus erythematosus, 16 about rheumatoid arthritis and 13 about juvenile rheumatic diseases. All of these studies included patients on GC (Tables 1, 2 and 3).5–50 The definition of osteoporosis as determined by bone mineral density (T-score <-2.5) and osteopenia (T-score <-1.0 to -2.5) should be the definition used for postmenopausal women;51 however, it is not applicable to GIO because patients on GCs can fracture at T-scores in the normal or osteopenic range. Along these lines, the International Society of Clinical Densitometry recommends the following definition: “below the expected range for age” for Z-scores lower than -2.0 and “within the expected range for age” for Z-scores above -2.0 for premenopausal women, children and adolescents instead of osteoporosis/osteopenia for GIO.52 Nevertheless, published reports use different definitions for diagnosing GIO, thereby limiting the effectiveness of study comparisons. For example, the term osteoporosis may not be used for patients with fractures and a bone mineral density greater than -2.5.53
GIO in systemic lupus erythematosus.
| Number (N) Population | Glucocorticoid association | Other associations with osteoporosis and osteopenia | Osteoporosis (%) | Osteopenia (%) | Fracture | References |
|---|---|---|---|---|---|---|
| N = 98, premenopausal women | Yes (cumulative GC dose with low lumbar spine BMD, and GC duration with low hip BMD) | No | 6.1% | 41.9% | Not described | Yeap et al., 2009 (5) |
| N = 100, premenopausal women | Yes (low BMD at hip) | Chronic disease damage, low BMI | 5.0% | 40% | Not described | Mendoza-Pinto et al., 2009 (6) |
| N = 40, men (mean age 42.6 years) | Yes (low BMD at lumbar spine) | Increased age, habitual drinking, low BMI | Not described | 30% | 5% | Mok et al., 2008 (7) |
| N = 163, women (median age 47 years) | No | Age, low weight, inflammatory markers, renal dysfunction, high chronic damage | 23% | Not described | Not described | Almehed et al., 2007 (8) |
| N = 60, premenopausal women | No | No | 6.6% | 46.7% | Not described | Chong et al., 2007 (9) |
| N = 307, 65% premenopausal women | No | Disease damage | Not described | Not described | Not described | Lee et al., 2006 (10) |
| N = 70, premenopausal women (mean age 31.8 years) | No | BMD | Not described | Not described | 21.4% | Borba et al, 2005 (11) |
| N = 107, 93% women (mean age 41.1 years) | Yes (vertebral fracture with intravenous methylprednisolone) | Low BMI | 4% | 39% | 20% | Bultink et al., 2005 (12) |
| Menopause | ||||||
| Vitamin D deficiency | ||||||
| N = 242, 95.4% women (median age 39.9 years) | Yes (low BMD) | Age, menopause | 10.3% | 50.8% | 9.1% | Yee et al., 2005 (13) |
| N = 205 patients | No | Age and damage index | 48.8% | 18% | Not described | Pineau et al., 2004 (14) |
| N = 118, premenopausal women | Yes (decreased BMD at lumbar spine and trochanter) | No | Not described | 1.4% | Not described | Uaratanawang et al., 2003 (15) |
| N = 32, women (mean age 43.2 years) | Yes (decreased BMD at lateral spine and total hip) | Not described | Not described | 68.7% | Not described | Boyanov et al., 2003 (16) |
| N = 79, women (mean age 49 years) | Yes (daily and cumulative dose) | High functional class | 23.7% | 61.9% | Not described | Bhattoa et al., 2002 (17) |
| N = 64 patients | No | Body weight, disease duration, and damage index | 10.9% | Not described | Not described | Becker et al., 2001 (18) |
| N = 23, men (mean age 45.6 years) | No | No | 17.4% | Not described | Not described | Bhattoa et al., 2001 (19) |
| N = 75, 88% women (median age 45 years) | Yes (low BMD at lumbar spine) | Age, BMI | 9% | 41% | Not described | Gilboe et al., 2000 (20) |
| N = 97, women (mean age 44.2 years) | Yes (low BMD at lumbar spine) | Not described | 13.4% | 44.3% | Not described | Kipen et al., 1997 (21) |
BMD, bone mineral density; BMI, body mass index; GC, Glucocorticoid; Osteopenia and osteoporosis defined using WHO classification.
GIO in rheumatoid arthritis.
| Glucocorticoid association | Other association with osteoporosis/osteopenia | Osteoporosis (%) | Osteopenia (%) | Fracture | References | |
|---|---|---|---|---|---|---|
| N = 97, women (mean age 58 years) | No | DAS, change in HAQ | 24% | 36% | Not described | Book et al., 2008 (22) |
| N = 209, 85.2% women (mean age 60.4 years) | Yes (fracture) | Functional class | Not described | Not described | 11.5% | Nampei et al., 2008 (23) |
| N = 74, premenopausal women | No | No | Not described | Not described | Not described | Hamalainen et al., 2007 (24) |
| N = 342, 83% women (mean age 42.6 years) | No | Joint radiological damage at baseline and at progression | Not described | Not described | Not described | Guler-Yuksel et al., 2008 (25) |
| N = 83, women (median age 47 years) | No | Age | 21.4% | 46.4% | Not described | Silva et al., 2007 (26) |
| N = 16, 75% women (mean age 47.2 years) | No | Not described | Not described | Not described | Not described | Habib et al., 2005 (27) |
| N-78, premenopausal women | Yes (osteopenia at lumbar spine) | No physical activity, low weight, high functional class, hand erosion, high ESR, anemia | Not described | Not described | 0 | Tourinho et al., 2005 (28) |
| N = 81, (mean age 48 years) 30.8% female | No | No | Not described | Not described | 11.1% | Van Everdingen et al., 2003 (29) |
| N = 410, (mean age 65 years) 90% premenopausal women | Yes (vertebral fracture) | No | Not described | Not described | 25% | de Nijs et al., 2001 (30) |
| N = 76, 61% women (mean age 54.8 years) | Yes (hip bone loss) | Postmenopausal women, low physical activity | Not described | Not described | Not described | Kroot et al., 2001 (31) |
| N = 75, 88% women (median age 45 years) | Yes (low BMD at lumbar spine) | Age and BMI | 4-5% | 28-44% | Not described | Gilboe et al., 2000 (32) |
| N = 85, 85.9% women (mean age 57 years) | Yes (decrease BMD at femoral neck) | Active and severe disease | Not described | Not described | Not described | Cortet et al., 1997 (33) |
| N = 195, postmenopausal women | Yes (cumulative GC dose with low femoral and whole body BMD) | Disability | Not described | Not described | Not described | Hall et al., 1993 (34) |
| N = 30, women (mean age 54 years) | No | Not described | Not described | Not described | Not described | Sambrook et al., 1989 (35) |
| N = 84, women (mean age 55.5 years) | No | Not described | 23.7% | 61.9% | 13.7% | Sambrook et al., 1986 (36) |
| N = 97, 90% women | Yes (distal forearm BMC) | Not described | Not described | Not described | Not described | Als et al., 1985 (37) |
BMD, bone mineral density; BMI, body mass index; DAS, Disease Activity Score; HAQ, Health Assessment Questionnaire; ERS, erythrosedimentation rate
GIO in juvenile rheumatic diseases.
| Disease | Number (n) Population | Glucocorticoid association | Other associations with low bone mass | Low bone mass (%) | Fracture | References |
|---|---|---|---|---|---|---|
| JIA/JCA/JRA | N = 62, 69.4% girls (median age 11.4 years) | No | No | Not described | 10% | Valta et al., 2007 (38) |
| JIA/JCA/JRA | N = 28, 57.1% girls (mean age 11 years) | Yes (low BMD at lumbar spine) | Age and age of disease onset | Not described | Not described | Celiker et al., 2003 (39) |
| JIA/JCA/JRA | N = 18, 38.9% girls (mean age 11 years) | Yes (low BMD at lumbar spine) | No | Not described | Not described | Cetin et al., 1998 (40) |
| JIA/JCA/JRA | N = 62, 58.1% girls (5–18 years) | Yes (low BMD at distal radius and lumbar spine) | Long disease duration | 50–60% | Not described | Pereira et al., 1998 (41) |
| JIA/JCA/JRA | N = 46 | Yes (fracture) | Not described | Not described | 50% | Varonos et al., 1987 (42) |
| Juvenile dermatomyositis | N = 20 girls (mean age 13.4 years) | Yes (GC pulse therapy with low BMD in hip) | Lean mass | Not described | Not described | Santiago et al., 2008 (43) |
| Juvenile dermatomyositis | N = 10 girls (mean age 11.8 years) | No | Weight | 70% | 0 | Castro et al., 2005 (44) |
| Juvenile dermatomyositis | N = 15, 60% girls (mean age 7.9 years) | No | Disease duration | 66.7% (Z <-1) | 33.3% | Stewart et al., 2003 (45) |
| Juvenile systemic lupus erythematosus | N = 36 girls (mean age 17.7) | No | Disease | 38.7% | 22.6% | Regio et al., 2008 (46) |
| Juvenile systemic lupus erythematosus | N = 70, 65% girls (mean age 26.4 years) | Yes (low bone mineral content) | Male gender | 41% | 6% | Lilleby et al., 2005 (47) |
| Juvenile systemic lupus erythematosus | N = 20, 90% girls (mean age 14.5 years) | Yes (BMD loss at lumbar spine) | No | Not described | Not described | Trapani et al., 1998 (48) |
| Juvenile systemic lupus erythematosus, JIA | N = 20, 65% girls (mean age 13.1 years) | No | No | Not described | Not described | Kashef et al., 2007 (49) |
| Juvenile dermatomyositis, juvenile systemic lupus erythematosus, vasculitis | N = 36, 91.6% girls (mean age 11.4 years) | Yes (lower BMD at lumbar spine, hip, total body) | Younger and prepubertal | 40% JSLE and 27% JDM/vasculitis | 0 | Alsufyani et al., 2005 (50) |
JIA, juvenile idiopathic arthritis; JCA, juvenile chronic arthritis; JRA, juvenile rheumatoid arthritis; DAS, Disease Activity Score; HAQ, Health Assessment Questionnaire
Studies on systemic lupus erythematosus demonstrate a frequency of osteoporosis from 4.0 to 48.8% and of osteopenia from 1.4 to 68.7%.5–21 Fractures were evaluated in four of these reports, with a frequency of 5.0 to 21.4%.7,11–13 A negative association between bone mass and glucocorticoid use was documented in ∼60% of these studies.5–7,13,15–17,20,21 Other possible associations with low bone mass in subjects with lupus were the chronicity of the disease, disease duration, low body mass index and weight, increased age, habitual drinking, positive serum markers of inflammation, renal dysfunction, menopause and physical dysfunction (Table 1).6–8,10–14,17–18,20
Rheumatoid ArthritisThe frequency of osteoporosis in patients with rheumatoid arthritis (RA) ranges from 4 to 24% and the frequency of osteopenia ranges from 28 to 61.9%.22,26,32,36 Fractures were evaluated in four studies out of 16, which showed a prevalence of osteoporosis of 0 to 25% in patients with rheumatoid arthritis;23,28,30,36 however, only two of these patients exhibited an association with GC use.23–30 De Nijs et al., showed that each 1 mg prednisone equivalent increase in the daily dose of GC increased the risk of vertebral deformities and symptomatic vertebral fractures in patients with RA.30 Glucocorticoid use was associated with decreased bone mass in 56.2% of subjects with RA.28,31–35,37 Bone loss was also related to the Disease Activity Score, a change in the Health Assessment Questionnaire, radiological joint damage, age, postmenopausal state, low physical activity, body mass index, disability, functional class and anemia (Table 2).22,23,25,26,28,31–34
Juvenile Rheumatic DiseasesSome studies have addressed GIO in juvenile idiopathic arthritis (JIA), which includes juvenile rheumatoid arthritis (JRA), juvenile chronic arthritis (JCA), juvenile systemic lupus erythematosus and juvenile dermatomyositis.38–50 The prevalence of low bone mineral density in children with rheumatic diseases is difficult to assess because various studies have used different cut-off points for Z-scores (e.g., < 1.0, < 2.0).41,44–47,50 Recently, the International Society of Clinical Densitometry defined low bone mineral density as a Z-score below –2.0 in children and adolescents in an attempt to standardize clinical data.52,54 In JIA, an association between glucocorticoid use and low bone mass was observed in four out of five studies.39–41 Santiago et al., found a relationship between pulse therapy with methylprednisolone (30 mg/kg per day for at least three days) and low bone mass in juvenile dermatomyositis.43 An association between glucocorticoid use and low bone mass was also observed in two studies that evaluated patients with juvenile systemic lupus erythematosus47,48 and in a study that evaluated several juvenile rheumatic diseases.49 Seven studies evaluated the prevalence of fractures and only one42 demonstrated an association with this complication (Table 3).38,42,44–47,50
Systemic SclerosisSeveral studies have assessed bone mass in patients with systemic sclerosis;55–58 however, only two reports included patients on glucocorticoid therapy.57,58 These authors did not find an association between osteoporosis and glucocorticoid use in this disease.57,58
Systemic VasculitisFew studies have addressed GIO in systemic vasculitis and only polymyalgia rheumatica and giant cell arteritis have been described.59–62 The frequency of osteoporosis has been shown to vary from 14.9 to 85%.60,61 Vertebral fractures were analyzed in a study that compared placebo with calcitonin and found an incidence of fractures between 11–14%.59
Guidelines for GIOThere are a number of guidelines regarding the management of GIO in patients who are receiving glucocorticoid treatment or that will be starting this therapy. We have reviewed the guidelines established by the American College of Rheumatology (ACR),63 the Department of Veterans Affairs Medical Centers (VMACs),64 the Dutch Society of Rheumatology (DSR)65 and the Royal College of Physicians (RCP).66 Various similarities among these four guidelines have been noted (Tables 4 and 5). All of these guidelines have recognized that even a short duration (3 months) of glucocorticoid use increases the risk of fracture and they recommend intervention. In addition, they suggest modification of life style risk factors (smoking cessation or avoidance, reduction of alcohol consumption if excessive and performance of weight-bearing physical exercises).63–66 The Royal College of Physicians' guidelines also reinforce the necessity to use the lowest GC dose possible.66
Guidelines for the prevention of GIO.
| American College of Rheumatology (49) | Department of Veterans Affairs Medical Centers (50) | Dutch Society of Rheumatology (51) | Royal College of Physicians (52) | |
|---|---|---|---|---|
| GC dose | ≥ 5mg/day | ≥ 5–7.5 mg/day | ≥ 7.5 mg/day | Not specified |
| Indication for calcium plus vitamin D | Yes | Yes | Not specified | Yes, if: |
| - low dietary calcium intake- vitamin D insufficiency | ||||
| Indication for densitometric evaluation before bisphosphonate | Yes, if: | Yes | Yes, if: | Yes, if: |
| - GC therapy ≥ 6 months | - GC 7.5–15 mg/day- premenopausal women- men < 70 yrs | - < 65 yrs- no previous osteoporotic fracture | ||
| Value of T-score to initiate bisphosphonate | Not specified | Not specified | < -2.5 | - 1.5 |
| Indication for bisphosphonate | - Prednisone ≥ 5 mg/day for ≥ 6 months | - Prednisone > 5 mg/day, except if BMD is normal- DXA is not available | - Prednisone > 15 mg/day- Fracture- Post-menopausal- Men > 70 yrs | - > 65 yrs (men and women)- Previous history of fragility fracture |
GC, Glucocorticoid
Guidelines for the treatment of GIO.
| American College of Rheumatology (49) | Department of Veterans Affairs Medical Centers (50) | Dutch Society of Rheumatology (51) | Royal College of Physicians (52) | |
|---|---|---|---|---|
| GC dose | ≥ 5mg/day | Not specified | Not specified | Not specified |
| Indication for calcium plus vitamin D | Yes | Yes | Not specified | Yes |
| Indication for densitometric evaluation before bisphosphonates | Yes | Yes | Not specified | Yes |
| Indication for bisphosphonate | BMD <-1.0 | - low BMD- history of fracture | Not specified | BMD <-1.5 or a reduction in BMD > 4% after 1 year |
GC, Glucocorticoid; BMD, bone mineral density
Although numerous guidelines for GIO management have been published, previous studies suggest that a relatively low percentage of patients who receive continuous glucocorticoid treatment are evaluated or administered preventive treatment for GIO. Saag et al., studied more than 3,000 adult men and women who had undergone long-term glucocorticoid therapy. These authors found that bone mineral density testing was performed in 19% of postmenopausal women and in 6% of women under the age of 50 years.67 The use of antiosteoporotic medication was most common among postmenopausal women and its use approached 50% in this group. In addition, the medical specialty of the physician providing care influenced both testing and treatment regimens. Notably, testing rates were 3 to 4 times greater in rheumatology practices than in internal medicine or family medicine practices.67,68 There are several possible explanations for these low compliance rates with current guidelines. For example, published guidelines are inconsistent regarding who should be treated. In addition, the dose and duration of glucocorticoid therapy are not standardized. Guidelines are also difficult to implement due to the physician's focus on the underlying disease. In select cases, there may be limited access to densitometry. Furthermore, patients and physicians may not have a clear perception of the risk of GIO and patients may not accept treatment. Our findings suggest that unification of guidelines regarding the glucocorticoid dose that would require treatment (such as prednisone equivalents ≥ 5 mg/day for at least 3 months), requirement of densitometric evaluation (premenopausal women and patients on GCs) and indication of bisphosphonates for prevention (postmenopausal women and men) and treatment (T-score < -1.0 or previous fragility fracture in postmenopausal women and men) could be of value to medical practioners.69
TreatmentBecause GCs induce an overall negative calcium balance, adequate calcium and vitamin D supplementation is important. A Cochrane Database Meta-Analysis concluded that calcium and vitamin D supplementation should be started in all patients who are administered glucocorticoids because of their low toxicity, low cost and the possible benefit in terms of fracture risk.70 Vitamin D is a hormone that increases intestinal calcium absorption and increases its reabsorption in distal renal tubules. Serum levels of at least 30 ng/mL (82 nmol/L), and optimally of 40–60 ng/mL, of 25-hydroxyvitamin D should be the target treatment regimen for GIO management. To achieve these levels, 1,000 to 2,000 IU of oral vitamin D daily may be necessary.71
Bisphosphonates are indicated for the prevention and treatment of GIO and most guidelines recommend the use of these drugs.63–66 The prevention and treatment goals of bisphosphonate use are stabilized or increased bone mineral density, as well as reduced frequency of fractures. A study using risedronate showed a decrease in vertebral fractures after one year of treatment.72 Currently, alendronate (70 mg/week or 10 mg/day) and risedronate (35 mg/week or 5 mg/day) are the only oral antiresorptive drugs that are recommended in GIO. Recently, zoledronic acid was approved for the prevention and treatment of GIO. In a multicenter, double-blind, double-dummy, randomized controlled trial that included 833 patients, a single 5 mg intravenous infusion of zoledronic caused a greater increase in bone mineral density than oral risedronate at 5 mg daily.73 Bisphosphonate treatment is recommended while patients are on glucocorticoids; however, in subjects with significant bone loss, therapy may need to be continued following the discontinuation of glucocorticoids.
Caution needs to be exercised when considering the use of bisphosphonates in women of childbearing age with GIO,63,74,75 given that bisphosphonates have an extended half-life and may cross the placenta with potentially unfavorable effects on fetal skeletal development. A recent review of 51 human cases examining exposure to bisphosphonates before or during pregnancy did not demonstrate skeletal abnormalities or other congenital malformations in the infants.75 Similarly, a related case-controlled study suggested that preconceptional and first-trimester use of bisphosphonates may pose limited fetal risk.76 Nevertheless, these studies included a small number of subjects and the safety of bisphosphonates in women of childbearing age, during pregnancy or while lactating is unknown. Therefore, physicians should carefully weigh the risks and benefits of bisphosphonate therapy in premenopausal women.
Although the guidelines do not address the use of anabolic therapies in GIO, this approach appears to be ideal because glucocorticoids reduce bone formation. Saag et al., published a randomized multicenter trial to compare use of oral alendronate (10 mg/day) and subcutaneous teriparatide (20 µg/day) over 18 months in patients with established GIO. The study showed that among patients with osteoporosis with a high risk for fracture, the bone mineral density increase in patients receiving teriparatide was greater than in those receiving alendronate.77 The study did not possess enough statistical power to detect differences in the incidence of fractures, although the number of vertebral fractures was significantly lower in the teriparatide arm than in the alendronate arm. Subsequently, the study was extended to 36 months and these results confirmed a higher increase in bone mineral density and fewer new vertebral fractures in subjects treated with teriparatide as compared to alendronate.78
CONCLUSIONAfter an extensive review of the literature, it was observed that the frequency of GIO varies due to different study designs and the lack of a uniform definition of GIO. Similarly, currently available guidelines use different recommendations for the prevention and treatment of GIO, thereby creating practical difficulties. Consequently, patients who are frequently exposed to GCs are not assessed or treated.
This work was supported by grants from National Council for Scientific and Technological Development (305691/2006-6 to R.M.R.P. and 300665/2009-1 to J.F.C.) and Federico Foundation (J.F.C. and R.M.R.P.).